Background: Thyrosulfoconjugation appears to facilitate fetal-to-maternal transfer of 3,3′-diiodothyronine-sulfate (T 2 s). elevated maternal levels of T 2 s cross-reactive material (compound W) are found in humans, with higher levels found in venous cord blood than in arterial samples. These findings are consistent with the postulate that the placenta plays an essential role in compound W production. Methods: serum compound W levels were measured by a T 2 s-specific radioimmunoassay in 60 serum samples from newborns with hyperbilirubinemia, age 1-30 d. In addition, 59 maternal serum samples, from day 1 to day 7 after uneventful deliveries, were studied. results: as compared with day 1, at day 5, the mean (±se) compound W level fell to 43.5 ± 6.8% (decay half-life (t 1/2 ) = 4.12 d) and to 33.7 ± 4.6% (decay t 1/2 = 2.82 d) in the newborn and maternal groups, respectively. In the mothers, the level continued to decline along the same slope through day 7. In the newborns, however, the mean compound W level entered a slower phase of decay after the fifth day with a decay t 1/2 = 10.9 d. conclusion: compound W is cleared at similar rates in newborn and postpartum maternal sera. This is consistent with the postulate that compound W is produced in the placenta.
i odothyronine sulfoconjugation is one of the major pathways of thyroid hormone metabolism in developing mammals (1, 2) . High serum concentrations of sulfated iodothyronine analogs have been shown in ovine and human fetal and newborn infant sera. These include thyroxine sulfate (T 4 S), 3,3′,5-triiodothyronine sulfate (T 3 S), reverse 3,3′,5′-triiodothyronine sulfate (rT 3 S), and 3,3′-diiodothyronine sulfate (T 2 S). A kinetic study using the steady-state constant infusion method in sheep showed that the major pathways of thyroid hormone metabolism in the fetus convert T 4 to the inactive metabolites rT 3 , T 4 S, rT 3 S, and T 3 S via sulfotransferase and type 3 deiodinase enzyme systems in late gestation (2, 3) . In sheep, thyrosulfoconjugation appears to facilitate fetal-to -maternal transfer of 3,3′-T 2 S, a metabolite from monodeiodination of both rT 3 S and T 3 S. In humans, a presumably similar process results in high maternal levels of T 2 S cross-reactive material (compound W) that disappears rapidly from maternal circulation after delivery (4, 5) . The measurement of compound W in maternal serum or urine during pregnancy may reflect iodothyronine levels in the fetus and therefore be a marker of fetal thyroid function (5, 6) . Compound W is not authentic T 2 S and, unlike T2S, is not hydrolyzed by hot acid. Hydrolyzable T 2 S constitutes a minor fraction of total T 2 S cross-reactivity in serum from mothers at term and in cord serum (4, 5) . A higher level of compound W has been found in venous cord blood than in arterial samples. These findings are consistent with the postulate that the placenta plays an essential role in compound W production and preferential transfer to the maternal compartment (ref. 4 and Figure 1 ). This study was conducted to answer the question: What are the relative rates of clearance of compound W from newborn and maternal postpartum sera?
Results
The age distributions and percentage reduction of compound W levels of the 60 newborn samples were shown as solid lines in Figure 2 . The percentage reduction of compound W levels in the newborns is presented as the average reduction on each postnatal day. The number of samples collected on each day was day 1, 10; day 2, 5; day 3, 5; day 4, 7; day 5, 4; days 7-10, 9; days 11-15, 8; days 18-22, 6; and days 24-32, 6. Fifty-nine postpartum maternal serum samples, from day 1 to day 7 after uneventful deliveries, were also studied. Maternal samples were collected as follows: day 1, 15; day 3, 22; day 5, 14; and day 7, 8. As shown in Figure 2 , at day 5 after delivery, the mean (±SE) compound W level was reduced to 43.5 ± 6.8% (decay half-life (t 1/2 ) = 4.12 d) and to 33.7 ± 4.6% (decay t 1/2 = 2.82 d) in newborn and maternal sera, respectively. In the postpartum mothers, the compound W level continued to decline along the same slope to 23.1 ± 2.2% at day 7. In the newborns, however, the mean compound W level declined Articles Chen et al.
along a slower slope after the fifth day to a level of 10.1 ± 1.2% at 24-30 d (t 1/2 = 10.9 d).
As shown in Table 1 , comparing liver function tests in newborns at days 2-5 (fast phase) and days 7-32 (slow phase), there are significant elevations of serum direct bilirubin and alkaline phosphatase levels in the slow phase. The total bilirubin was 257 ± 15 µmol/l at 2-5 d as compared with 293 ± 24 µmol/l at 7-32 d (not significant). The direct bilirubin was 3.5 ± 1.1 µmol/l at 2-5 d as compared with 9.3 ± 1.5 µmol/l at 7-32 d (P < 0.01). The alkaline phosphatase was 129 ± 8 IU/l at 2-5 d as compared with 213 ± 14 IU/l at 7-32 d (P < 0.001).
DIsCussIoN
In humans, we have shown high levels of compound W in maternal serum (4, 5) and urine (6) . Levels increased with the progression of pregnancy and peaked before parturition. At delivery, a 20-fold increase in serum compound W was found as compared with levels in nonpregnant women, and levels returned to nonpregnant values by 7-10 d. The compound W in maternal serum did not co-chromatograph with synthetic T 2 S by high-performance liquid chromatography (4) and, in contrast to authentic T 2 S, was not hydrolyzed by hot-acid digestion. Using hot-acid digestion, the recovery of compound W was 77.1% in fetal and 87.4% in maternal serum (5) .
To explore the possible origin of compound W, the serum concentrations of sulfated iodothyronines from cord arterial and venous samples were compared. There were no significant differences between the mean T 3 S, T 4 S, or rT 3 S concentrations of arterial and venous serum samples. However, the mean compound W concentration in paired arterial/venous cord sera was significantly higher in venous than in arterial samples (5). In addition, the maternal serum concentrations were significantly lower than those of the paired cord serum. These findings support the postulate that compound W is produced in the placenta. The rapid disappearance from both maternal and newborn sera immediately after delivery in this study supports this hypothesis.
In the newborns, there was a slower phase of compound W decay after the fifth day through days 24-30 with a decay t 1/2 = 10.9 d. Possible liver dysfunction related to the elevated direct bilirubin and alkaline phosphatase ( Table 1 ) may have played a role in the slower metabolism of compound W.
Prior studies suggest strongly that compound W is a metabolite of fetal thyroid hormone capable of transplacental fetal-tomaternal transfer (3) (4) (5) 7) . Both maternal and fetal compound W levels increased progressively during gestation with significant direct correlation (in both mothers and fetuses). In addition, in paired cord and maternal sera obtained at delivery, highly significant positive correlations were observed between respective compound W levels and fetal free thyroxine (FT 4 ) (5). A significant positive correlation was also observed between maternal and fetal compound W whereas no correlation was observed between maternal serum compound W and maternal serum FT 4 in euthyroid or hyperthyroid women. These data suggest that fetal FT 4 contributes significantly to placental production of compound W. Therefore, the concentration of compound W in maternal serum reflects fetal thyroid function. However, the presence of significant compound W levels in maternal serum during the first trimester contradicts this conclusion because fetal thyroid hormones are supplied by the mother only before the onset of hormonal synthesis in fetal thyroid gland at midgestation. Our current postulate is that compound W is produced in the placenta from substrate T 2 S in the fetal circulation. In turn, the amount of T 2 S is determined by the T 4 and T 3 levels, whether from mother or fetus, present in the fetal circulation.
Studies indicate that abnormalities in intelligence quotient and other neuropsychological tests may be found in children of women with subclinical hypothyroidism during pregnancy Articles T 2 S cross-reactive material in newborns (8) (9) (10) . However, in a recent report (11) , women who had severe hypothyroidism in early pregnancy, but who were restored to normal later in pregnancy, had offspring who developed normally. The authors postulate that iodine deficiency may be the factor that leads to abnormal development. In any case, we have no data on maternal levels of compound W in this group of mothers. In a prior study, Cortelazzi et al. (7) found no significant correlation between serum levels of maternal compound W and maternal FT 4 . However, these serum samples were collected from pregnant women of different gestational ages. It is possible that any significant correlation between maternal FT 4 and maternal compound W levels before the onset of fetal function may be negated by fetal T 4 secretion in the later trimesters. Nevertheless, whether maternal hypothyroidism may result in lower compound W values in the first trimester is yet to be studied. Maternal compound W levels also seem to reflect the effects of drugs on fetal thyroid function. In women on propylthiouracil, maternal serum compound W levels were in the low normal range and did not show the usual increase with progression of gestation (7) . The lack of progression in maternal compound W levels was confirmed in a recent study of 22 pregnant women treated with antithyroid medication (12) . A significant increase in maternal compound W was observed when the propylthiouracil dose was decreased or discontinued.
Cortelazzi, et al. (7) suggest that fetal hypothyroidism is predictable by the absence of the normal rise of compound W during gestation. Serial measurements of compound W in maternal serum can be considered a safe and practical test for the assessment of fetal thyroid function, particularly in hyperthyroid women treated with antithyroid drugs (12) .
At present, there is no practical and noninvasive marker for fetal thyroid function available to specialists managing highrisk pregnancies. Amniotic fluid levels of T 3 , T 4 , and thyroidstimulating hormone do not consistently reflect fetal plasma concentrations, and direct assessment via percutaneous umbilical cord blood sampling carries a 1% risk of fetal mortality (13) . Serial ultrasonographic examinations are relatively cumbersome (14) . The possibility that the transferred compound W may serve as a convenient and noninvasive marker of fetal thyroid function deserves further exploration.
In conclusion, our result, showing that T 2 S cross-reactive material (compound W) is cleared from newborn and postpartum maternal sera at similar rates is consistent with the postulate that compound W is produced in the placenta. The rate of decay in the newborn may be affected by coexisting hyperbilirubinemia, which may partially explain the slower phase of decay in infants returning after 5 d of follow-up. Additional data on decay of compound W in normal healthy newborns would provide useful information, and such studies are planned.
MetHoDs
Serum compound W levels were measured by radioimmunoassay using a polyclonal antibody against T 2 S. Labeled T 2 ( 125 I-3,3′-T 2 ) was prepared by radioiodination with 125 I (NEZ033L) from NENPerkinElmer (Boston, MA) using the method described previously (15, 16) . The anti-L-T 2 S antibody (W0213) was obtained from rabbits immunized with a 3,3′-T 2 S-bovine serum albumin conjugate (4). T 2 was purchased from Henning-Berlin (Berlin, Germany). The lower limit of detection of the assay was 3.3 fmol (2 pg), or 33.1 pmol/l in a 300 µl ethanol extract of serum. Intra-assay variations were 1.9-9.1% and interassay variations were 6.0-19.5%, depending on the measured concentrations.
Sixty serum samples, from newborns aged 1-30 d (38 males), were studied. These are banked sera collected for clinical management of neonatal hyperbilirubinemia (total bilirubin is 95-364 µmol/l; normal range, 1.7-20 µmol/l). The gestational age of the newborns averaged 38.7 wk (range 36.0-41.9). No neonatal hypothyroidism (thyroid-stimulating hormone >20 mU/l) was found in this group of newborns (17) . Samples from newborns with gestation period <36 wk were excluded. All blood-sampling protocols were approved by the institutional review board of the Wuxi Hospital for Maternal and Child Health Care. Because anonymous banked serum samples were used in the study, the institutional review board determined that no informed consent was needed. Banked serum samples were stored at −20 °C in the clinical laboratory and studied within 12 mo. Preliminary studies have shown that frozen samples at the same temperature are stable for 1 y in repeat measurement of compound W, 101.2 ± 2.5% (mean ± SE, percentage of initial values of compound W, n = 14) (S.Y.W., unpublished data).
In addition, 59 maternal (unrelated to newborns studied) serum samples, from day 1 to day 7 after uneventful deliveries, were also studied. Compound W levels, expressed as ng/dl of T 2 S-equivalent in 
Mean ± se 27.6 ± 3.5 293 ± 24 9.3 ± 1.5 36.8 ± 0.5 16.9 ± 2.9 44.3 ± 4.6 152 ± 14 213 ± 14 P < 0.001 Ns P < 0.01 P < 0.002 Ns Ns Ns P < 0.001 aLB, albumin; aLK, alkaline phosphatase; aLT, alanine aminotransferase; asT, aspartate aminotransferase; DB, direct bilirubin; GGT, γ-glutamyl transpeptidase; Ns, nonsignificant; TB, total bilirubin; W, compound W (3,3′-diiodothyronine sulfate cross-reactive material).
a Mean ± se compound W value as a percentage of the mean of day 1 level.
